Welcome to our dedicated page for Vivos news (Ticker: RDGL), a resource for investors and traders seeking the latest updates and insights on Vivos stock.
Vivos Inc. develops isotope-based radiotherapeutic products for targeted cancer treatment and related therapeutic applications. News about RDGL centers on RadioGel® for human use, IsoPet® for veterinary applications, and the company’s Precision Radionuclide Therapy™ approach, which is designed to deliver localized beta radiation directly to tumor sites while limiting exposure to surrounding tissue.
Recurring developments include FDA IDE-related work for RadioGel®, international human therapy demonstrations, veterinary clinic certification and IsoPet adoption, intellectual-property protection for hydrogel and radiotherapy technology, manufacturing arrangements for yttrium-90 phosphate particles and sterile hydrogel doses, and strategic collaborations in companion-animal radiotherapeutics.
Vivos Inc. (OTCQB: RDGL) has successfully completed its first IsoPet® therapy on a horse with a tumor at the University of Missouri. This marks an expansion of IsoPet® into the equine market, providing a unique treatment option for larger animals. The horse's tumor has already stopped growing post-treatment. Dr. Mike Korenko emphasized the importance of this development for the company's business strategy, aiming to further refine the technique and collaborate with a private clinic. Interested horse owners can now express their interest in the therapy via the company’s website.
Vivos Inc. (OTCQB: RDGL) has successfully extended its IsoPet® trademark protection internationally, confirmed by the U.S. Patent and Trademark Office. The isopet trademark is now registered with the World Intellectual Property Organization (WIPO) for veterinary isotopes. Countries like Australia, Canada, and the UK have 18 months to object to this registration. Dr. Korenko emphasized the significance of this development for Vivos' global branding mission in pet cancer treatment. The IsoPet® solution utilizes Yttrium-90 for targeted brachytherapy in animals and humans, indicating promising therapeutic advancements.
Vivos Inc. (OTCQB: RDGL) has enhanced its manufacturing processes for Radiogel™, crucial for FDA compliance in upcoming clinical trials. Key improvements include fifteen polymer runs and over fifty new Quality Management System documents, along with new precision process control equipment. These efforts aim to accelerate pre-clinical testing and strengthen IDE submission to the FDA, expected within 90-120 days. The company is also exploring contracts for international production of RadioGel™ and IsoPet®. CEO Korenko emphasized that these advancements make the company a serious contender in cancer treatment for both animals and humans.
Vivos Inc (RDGL) has announced its participation in the LD 500 investor conference, scheduled for September 3, 2020, at 1:40 PM PST. Dr. Mike Korenko, CEO, will present virtually, emphasizing the accessibility of this event amid COVID-19 restrictions. The conference runs from September 1 to 4, offering a platform for unique companies in the microcap space. Vivos specializes in an Yttrium-90 based injectable brachytherapy device for treating tumors in humans and animals, utilizing proprietary hydrogel technology for targeted radiation treatment.